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Background. Several long-term cohort studies and in-vitro fitness assays have resulted in inconsistent reports on changes in
HIV-1 virulence, including reports of decreasing, stable, and increasing virulence over the course of the AIDS pandemic. We
tested the hypothesis of changing HIV-1 virulence by examining trends in prognostic clinical markers of disease progression
from 1984 to 2005 among nearly 400 antiretroviral-naı¨ve participants in the United States Multicenter AIDS Cohort Study
(MACS), a longitudinal study of HIV infection in men who have sex with men (MSM). Methodology/Principal Findings.
Because clinical AIDS endpoints could not be used (due to antiretroviral therapies and prophylaxis), three prognostic markers
of disease progression were used as proxies for HIV-1 virulence: plasma viral RNA load and CD4+ T cell count at ‘‘set point’’
(between ,9 and ,15 months after seroconversion), and rate of CD4 cell decline within three years after seroconversion. We
performed multivariate analyses of the association between these markers and seroconversion year, with covariates including
MACS site, race/ethnic group, seroconversion age, and CCR5D32 status. No statistically significant association was found
between year of seroconversion and ‘‘set point’’ plasma viral load (at ,9 months after seroconversion: slope =20.004 log10
copies/mL/year, p = 0.76; at,15 months: slope =20.005 log10 copies/mL/year, p = 0.71), CD4 cell count after seroconversion (at
,9 months: slope =20.112 cells/mL/year, p = 0.22; at ,15 months: slope =20.047 cells/mL/year, p = 0.64), or rate of CD4 cell
decline over the first three years after seroconversion (slope =20.010 cells/ul/yr2, p = 0.88). Conclusions/Significance. The
lack of significant trends from 1984 to 2005 in these prognostic markers of HIV disease progression suggests no major change
in HIV-1 virulence over the AIDS pandemic in MSM in the US.
Citation: Herbeck JT, Gottlieb GS, Li X, Hu Z, Detels R, et al (2008) Lack of Evidence for Changing Virulence of HIV-1 in North America. PLoS ONE 3(2):
e1525. doi:10.1371/journal.pone.0001525
INTRODUCTION
Whether HIV-1 has become more or less virulent since its
introduction into the human population has significant implica-
tions for the course of the AIDS pandemic. Over the last two
decades, several studies of long-term cohorts have resulted in
conflicting data on this question, including reports of increasing
[1–4], stable [5–10], and decreasing virulence [11]. There are also
contrary reports of changing HIV-1 virulence based on in-vitro
competitive viral fitness data used as proxies for virulence. Arien et
al. [12,13] found HIV-1 replication capacity was greater in early
(1986–1989) than in recent isolates (2002–2003) from Belgium
(n = 24), and suggested that HIV may be attenuating over time. In
contrast, Gali et al. [14], using the same in-vitro methods in an
Amsterdam cohort (n = 25), found that HIV replication capacity
was greater in recent (late 1990s) than in earlier isolates (mid-
1980s), suggesting the opposite conclusion. In a recent large study
of 22 cohorts from Australia, Canada, and Europe, Dorrucci et al.
(2007) found trends of decreasing CD4+ T-cell counts (n = 3687)
and increasing viral loads (n = 1584) in measurements at
,4 months after seroconversion between 1985 and 2002,
suggestive of increasing HIV-1 virulence over time [1–4].
Studies of host-pathogen interactions suggest that hosts and
pathogens can co-adapt to each other, with pathogens becoming
less virulent over time [15]. Possible examples of this phenomenon
are primate lentiviruses such as SIVcpz (HIV-1) in chimpanzees
and SIVsm (HIV-2) in sooty mangabeys, viruses that cause no
apparent disease in their natural hosts [16,17]. Attenuation of
HIV-1 could result from the decrease in viral fitness that often
accompanies viral evolution away from host cytotoxic T-
lymphocyte (CTL) and humoral immune responses [18,19]. In
addition, data suggest that the accumulation of drug resistance
mutations can reduce the replication capacity of HIV-1 [20],
which could concomitantly lead to reduced virulence. Conversely,
it is also possible that HIV-1 may be under selection for increased
virulence in the human population, as higher viral loads are
associated with increased probability of transmission [21–23].
Pathogen virulence is most commonly measured in host
mortality [15]. For HIV-1, the most direct measure of virulence
is the time from initial infection to the development of clinical
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AIDS and death. Thus, evidence for decreased virulence of HIV-1
would be a lengthening interval from infection to AIDS and death
over the course of the epidemic. We tested the hypothesis of
changing HIV-1 virulence by examining trends in rate of progression
of HIV-1 infection in men followed in the Multicenter AIDS Cohort
Study (MACS) from 1984 to 2005. Prognostic markers of disease
progression had to be used as endpoints, because direct measures of
this rate, such as time from seroconversion to AIDS and death, have
been dramatically affected over the second half of this interval by the
advent of potent antiretroviral therapies and by progress in
prophylaxis and treatment of opportunistic infections and AIDS-
related malignancies. Of the multiple prognostic markers of HIV-1
disease progression, we selected 1) the viral set point, defined as the
plasma viral RNA level at the second or third semiannual visit after
seroconversion, because it has been shown to be the strongest single
early predictor of disease course [24–27], and 2) the CD4 cell count
and the slope of its decline, because these markers have commonly
been used in cohort-based analyses of long-term changes in HIV
virulence [1,3,6,7].
RESULTS
The demographic characteristics of the study population are
shown in Table 1. The median plasma viral load at the second
seropositive visit (,9 months after seroconversion) was 4.485 log10
copies/mL (n= 357); at the third seropositive visit (,15 months)
this figure was 4.399 log10 copies/mL (n= 318) (Table 1). The
median CD4 cell count was 624 cells/mL (n= 375) at the second
visit and 588 cells/mL (n= 348) at the third visit (Table 1).
We found no significant trends in set point plasma viral load
over the 20-year study period, in either univariate or multivariate
models. For the viral load at the second seropositive visit, the slope
was 20.004 log10 copies/mL/year, (p = 0.76; Table 2); for the
third seropositive visit the slope was 20.005 log10 copies/mL/year
(p = 0.71; Table 2). Among the covariates examined in the
multivariate model, only heterozygosity of the coreceptor allele
CCR5D32 showed a significant association with viral setpoint
(Table 2) (no participant was CCR5D32 homozygous).
In the CD4 cell count analysis, we found no significant
association between calendar year of seroconversion and the
square root-transformed CD4 cell count at either the second or
third seropositive visits, in either univariate or multivariate
analysis. Specifically, the slope of the square root-transformed
CD4 cell count at the second seropositive visit was 20.112 cells/
mL/year (p = 0.22; Table 2); and at the third seropositive visit this
slope was 20.047 cells/mL/year (p = 0.64; Table 2). Similarly,
there was no correlation between calendar year of seroconversion
and rate of CD4 cell decline over the first three years after
seroconversion, in either univariate or multivariate models
(slope =20.010 cells/ul/yr2, p = 0.88; Table 3). None of the
covariates examined was significantly associated with either the
CD4 cell count at the second or third seropositive visit, or its slope
over the first three years after seroconversion (Table 2, Table 3).
In the analysis of the mean of the second and third seropositive
visits (if data was available for both visits, only one visit if only visit
had data available), we found no significant temporal trend in viral
load (n= 384, slope=20.005 log10 copies/mL/year, p= 0.66)
(Table 3) (Figure 1). We found a slight decreasing trend in square-
root transformed CD4 cell count (n = 409, slope =20.138 cells/
mL/year, p= 0.10) (Table 3) (Figure 2). These trends translate to
decreases of of ,0.1 log10 copies/mL in viral load set point and
,7 cells for the CD4 cell count over the 20 year study period;
neither of these values is clinically significant.
All of the above analyses were also done using calendar years in
bins comprised of data from 5 year intervals, and yielded results
consistent with the above analyses of individual calendar years. We
also tested for a trend over time in the lag between estimated date
of seroconversion and the second and third seropositive visits; no
trend was found.
DISCUSSION
We tested for associations between calendar year of seroconversion
and three prognostic markers of disease progression in the MACS
cohort between 1984 and 2005. Our results showed no significant
trends in set point plasma viral RNA load, CD4 cell count after
Table 1. Summary of participants and data.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Los Angeles 130 31.48
Pittsburgh 98 23.73
CCR5D32 heterozygous N %
- 337 83.21
+ 68 16.79
CD4+ T-cell count N Median (IQR)
1st 408 730 (539, 921)
2nd 375 624 (454, 837)
3rd 348 588 (453, 799)
2nd/3rd mean 409 600 (459, 817)
Plasma log10 viral load N Median (IQR)
1st 375 4.434 (3.90, 4.96)
2nd 357 4.485 (3.95, 4.87)
3rd 318 4.399 (3.95, 4.77)
2nd/3rd mean 384 4.499 (3.99, 4.81)






Demographics of participants examined in this study; Characteristics of
prognostic markers of HIV-1 disease at the first three visits (1st, 2nd, 3rd) or a
combination of the data available from the 2nd and 3rd visit after seroconversion
(,3, ,9, and ,15 months) in MACS participants from 1984 to 2005, prior to
any antiretroviral therapy; Number of participants with prognostic marker data
by year in quartiles, using the mean of the second (,9 mos.) and third (,15
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seroconversion, or the rate of CD4 cell decline in the first three
years after seroconversion. Moreover, estimates of change in these
markers over time were very close to zero. Thus, the results of this
study do not support the hypothesis that there has been any
important change in the virulence of HIV-1 over this time period
in this cohort. This is consistent with recent findings that revealed
no long-term changes in virulence over 20 years in a Swiss cohort
[10], and with a previous analysis of MACS participants that
reported stable rates of CD4 cell loss between 1984 and 1991 [6].
Our results are contrary to those from studies of long-term
cohorts have found decreasing [11] or increasing [1–4] virulence
over time. The largest study to date, by Dorrucci et al. [4],
analyzed Australian, Canadian, and European cohorts from 1985
to 2002, and found a decreasing trend in the first CD4 cell count
(n = 3687) and an increasing trend in the first viral load (n= 1584)
after seroconversion. That study used the first CD4 cell count after
seroconversion, with a median lag time between seroconversion
and CD4 cell count of,4 months; we used CD4 cell counts at,9
and ,15 months after seroconversion. In order to more directly
compare our and Dorrucci et al.’s results, we estimated trends from
1984 to 2005 in the plasma viral load and CD4 cell count at the
first seropositive visit in the MACS cohort, corresponding to
,3 months after seroconversion. We again found no significant
association between viral load and seroconversion year (n = 375,
slope =20.011 log10 copies/mL/year, p = 0.48, 95% CI –0.042 to
0.020), but did observe a decreasing trend in square-root
transformed CD4 cell count (n = 408, slope=20.194 cells/mL/
year, p = 0.03, 95% CI –0.363 to –0.024). We suspect this result,
and the discrepancy between our analyses at ,9 and ,15 months
after seroconversion and those of Dorrucci et al., may be due to the
significant CD4 cell fluctuations that occur during acute and early
infections [25,28]. By ,9 and ,15 months after seroconversion
CD4 cell counts have likely recovered and stabilized from these
fluctuations. It will be beneficial to examine trends in viral load
and CD4 cell count at later timepoints after seroconversion in the
Dorrucci et al. cohorts.
Our results are also contrary to the recent inference of HIV-1
attenuation based on in-vitro competitive fitness data between early
(1986–1989) and recent isolates (2002–2003) from Belgium
[12,13]. However, Gali et al. [14] used the same fitness assay
approach in a study comparing Amsterdam Cohort Studies
samples from the mid-1980s against samples from the late 1990s,
Table 2. Multivariate analyses of prognostic markers of HIV-1 disease.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Plasma viral load (log10) CD4 cell count*
copies/mL/year cells/mL/year
a) N = 357 N= 375
Estimate P 95% CI Estimate P 95% CI
Calendar year of SC 20.004 0.76 20.030, 0.021 20.112 0.22 20.289, 0.066
Age at SC (per 10 yr increase, centered at 30 yrs) 0.088 0.11 20.022, 0.199 20.267 0.5 21.036, 0.503
MACS site (Pittsburgh used as reference)
Baltimore 20.091 0.47 20.337, 0.156 1.411 0.1 20.293, 3.114
Chicago 20.107 0.42 20.369, 0.154 20.388 0.67 22.202, 1.426
Los Angeles 20.129 0.28 20.364, 0.106 0.575 0.48 21.004, 2.153
Race/ethnicity (White, non-Hispanic used as reference)
Black, non-Hispanic 0.098 0.55 20.228, 0.423 0.142 0.91 22.254, 2.537
Hispanic 20.12 0.5 20.471, 0.230 20.269 0.84 22.855, 2.318
Other 20.265 0.73 21.778, 1.248 26.062 0.28 217.041, 4.916
CCR5D32
Heterozygous 20.441 ,0.0001 20.655,20.227 0.672 0.4 20.880, 2.223
b) N = 318 N= 348
Estimate P 95% CI Estimate P 95% CI
Calendar year of SC 20.005 0.71 20.032, 0.022 20.047 0.64 20.244, 0.151
Age at SC 0.038 0.49 20.068, 0.144 0.024 0.95 20.758, 0.805
MACS site
Baltimore 20.101 0.41 20.338, 0.137 1.684 0.06 20.069, 3.437
Chicago 0.01 0.92 20.237, 0.258 21.288 0.17 23.128, 0.548
Los Angeles 20.038 0.74 20.263, 0.188 20.088 0.92 21.732, 1.556
Race/ethnicity
Black, non-Hispanic 20.041 0.8 20.359, 0.277 20.03 0.98 22.610, 2.550
Hispanic 0.002 0.99 20.327, 0.331 20.018 0.99 22.637, 2.601
Other 20.318 0.65 21.673, 1.037 24.28 0.44 215.121, 6.561
CCR5D32
Heterozygous 20.441 ,0.001 20.641, 20.241 0.297 0.7 21.242, 1.836
SC= seroconversion, CI = confidence interval, * square root-transformed
a) Data from second seropositive visit (,9 months after estimated date of SC) versus calendar year of SC, 1984 to 2005. b) Data from third seropositive visit
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matched for time since seroconversion, coreceptor usage, and viral
subtype. They found that the recent isolates had higher fitness
than earlier isolates, and suggested HIV-1 virulence may be
increasing in this cohort. The number of isolates tested in these
two studies was small (n = 24 and 25, respectively). As hinted at by
these discrepant results, it is possible that changes in in-vitro fitness
are not directly or easily compared to clinical prognostic markers
or virulence in humans, and that larger sample sizes may be
required in these assays.
Host factors (and potentially other unknown factors) can affect
rates of disease progression independently of viral load [29]; it is
possible that existing variation in progression rates to AIDS or death
in the MACS is not reflected in the viral load or CD4 cell count data
we examined. However, it is unlikely that allele frequencies of
particular host factors (e.g. CCR5D32, CCL3L1) have changed
significantly in humans between 1984–2005. HIV-1 subtypes can
vary in disease progression rates independently from viral load as
well [30]. Yet we believe that all, or at least the vast majority, of the
subjects in this study are infected with subtype B, as there have been
no reports of non-subtype B virus in the MACS to this date.
Our study has some limitations. First, seroconverters in the
MACS cohort were significantly more frequent in the first decade
of the study period than in later years. Second, even though the
MACS followed large numbers of seroconverters until clinical
AIDS or death, we were unable to use those disease outcomes in
our analyses because calendar year is linked to progress in HIV/
AIDS disease management (e.g., prophylaxis and treatment of
opportunistic infections, and development of more potent
antiretroviral therapies). Thus, we had to rely on prognostic
markers to study trends in HIV-1 disease progression rates. Third,
because we excluded men who started antiretroviral therapy, there
is a possible selection bias; men who experienced disease
progression would not contribute to our analysis, and any decrease
of the mean time from seroconversion to first therapy (into the
second or third seropositive visit) over the study period would not
be detected. However, the number of men excluded is small (for
Table 3. Multivariate analyses of prognostic markers of HIV-1 disease.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
a) Plasma viral load (log10) CD4 cell count*
copies/mL/year cells/mL/year
N=384 N= 409
Estimate P 95% CI Estimate P 95% CI
Calendar year of SC 20.005 0.66 20.030, 0.019 20.138 0.1 20.302, 0.025
Age at SC 0.092 0.07 20.009, 0.193 20.094 0.79 20.791, 0.604
MACS site
Baltimore 20.15 0.19 20.372, 0.072 2.083 0.01 20.529, 3.636
Chicago 20.078 0.51 20.311, 0.156 20.407 0.62 22.037, 1.223
Los Angeles 20.059 0.58 20.270, 0.151 0.541 0.46 20.891, 1.973
Race/ethnicity
Black, non-Hispanic 0.083 0.57 20.206, 0.372 20.403 0.71 22.539, 1.732
Hispanic 20.064 0.69 20.378, 0.250 20.529 0.65 22.816, 1.759
Other 20.311 0.67 21.731, 1.108 25.244 0.32 215.611, 5.123
CCR5D32
Heterozygous 20.426 ,0.001 20.622,20.231 0.644 0.37 20.764, 2.053
b) Rate of CD4 cell decline{
cells/uL/yr2
N = 422
Estimate P 95% CI
Calendar year of SC 20.01 0.88 20.133, 0.114
Age at SC 0.418 0.12 20.946, 0.111
MACS site
Baltimore 0.995 0.09 20.166, 2.157
Chicago 0.323 0.61 20.902, 1.548
Los Angeles 0.822 0.13 20.243, 1.888
Race/ethnicity
Black, non-Hispanic 21.613 0.05 23.211, 20.015
Hispanic 22.051 0.02 23.756, 20.347
Other 0.702 0.86 27.197, 8.601
CCR5D32
Heterozygous 0.739 0.17 20.326, 1.803
SC= seroconversion, CI = confidence interval, { within 3 years of SC, * square root-transformed
a) Data using the mean of the second (,9 months) and third (,15 months) seropositive visits, or one of these visits if data was not available from both. b) The slope of
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Figure 1. RNA viral loads through time. A) Boxplot for the mean of log10 HIV RNA at second and third seropositive visits (,9 and,15 months after
estimated date of seroconversion) by calendar period of seroconversion. The horizontal line in the interior of the box denotes the median; and the
height of the box is equal to the interquartile distance (IQD). The whiskers (the dotted lines extending from the top and bottom of the box) extend to
the extreme values of the data or a distance 1.56IQD from the center, whichever is less. The horizontal lines falling outside the whiskers represent
outliers. B) Relationship between the mean of log10 HIV RNA at second and third seropositive visits and calendar year of seroconversion. Three solid
lines are the fitted regression line and its 95% confidence bands from univariate linear regression (note that slope estimates reported in manuscript
text are from multivariate analysis).
doi:10.1371/journal.pone.0001525.g001
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viral load analysis, n = 5 at first seropositive visit, n = 14 at second,
n = 16 at third; for CD4 analysis, n = 6 at first seropositive visit,
n = 20 at second, n = 18 at third; for CD4 slope analysis, n = 28 in
the first three years after seroconversion), and this likely did not
impact our analyses. Fourth, we could not correct for the changes
in laboratory methods for CD4 or viral load measurements over
this time period, as the these changes correlate completely with
year (and we are looking for changes in estimates of these markers
Figure 2. CD4+ T cell levels through time. A) Boxplot for the mean of square-root transformed CD4+ T-cell count at second and third seropositive
visits (,9 and ,15 months after estimated date of seroconversion) by calendar period of seroconversion. Boxes are defined as in the legend to
Figure 1. B) Relationship between the mean of square-root transformed CD4+ T-cell count at second and third seropositive visits and calendar year of
seroconversion. Three solid lines are the fitted regression line and its 95% confidence bands from univariate linear regression (note that slope
estimates reported in manuscript text are from multivariate analysis).
doi:10.1371/journal.pone.0001525.g002
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by year). This issue is one that plagues all similar studies, including
Dorrucci et al. (2007). Lastly, although we found no significant
changes in set point viral load over the 20 years of observation, the
95% confidence intervals encompass a range of ,20.6 to +0.4
log10 copies/mL over this period (Table 2), which is greater than
the 0.3 log10 copies/mL cut-off that has been used as a ‘‘clinically
significant’’ change in this marker [24,25].
In conclusion, our data suggest that there has been no change in
HIV-1 virulence over the last 20 years in the MACS cohort.
However, it is unclear if more frequent and earlier use of highly
active antiretroviral therapy will have an eventual negative impact
on transmission and subsequent HIV virulence, or if the
association between higher viral loads and transmission risk will
eventually select for greater virulence in the human population.
MATERIALS AND METHODS
Study population
The Multicenter AIDS Cohort Study (MACS) is an ongoing
prospective study of the natural and treated histories of HIV-1
infection in homosexual and bisexual men conducted by sites located
in Baltimore, Chicago, Pittsburgh and Los Angeles [31]. A total of
6,972men have been enrolled during three enrollment periods: April
1984 through March 1985 (n=4954), April 1987 through
September 1991 (N=668), and October 2001 and August 2003
(n= 1350). MACS participants were seen during semi-annual visits
at one of the study sites where they underwent standardized
questionnaires, physical examinations and laboratory assessments
[31]. Study participants in the MACS provided written informed
consent and IRB approval for this study was obtained from the
University of Washington and the MACS parent institutions.
At the time of the present analysis, there were 2884 men who
had entered the study as HIV-seroprevalent, and 596 men with a
known date of seroconversion. Estimated date of seroconversion
was the median time between the last seronegative visit and the
first seropositive visit. For each participant, we included only data
from visits prior to the start of any antiretroviral treatment
(including any mono-, dual-, or highly active antiretroviral therapy
(ART)). We further restricted the analysis to those 483
seroconverters who had less than one year between their last
seronegative and first seropositive visits. Of these, 357 had plasma
viral load measurements at ,9 months after estimated date of
seroconversion, and 318 had viral load measurements at
,15 months after seroconversion date. The corresponding
numbers for CD4 cell counts were 375 and 348, respectively
(Table 1). To increase the sample sizes in our analyses, we also
tested for associations between prognostic markers and year of
seroconversion using combined data from the second and third
seropositive visits. The mean of the two visits was used if data was
available for both visits; if data from only one of these visits was
available, that value was used. This approach increased overall
numbers included to 384 for plasma viral load and 409 for CD4
cell count, and also reduced potential lag-time or outlier bias.
The 596 men with known dates of seroconversion included 59
men from Pittsburgh who enrolled in the MACS already
seroprevalent but with a known seroconversion date; 49 of these
men had less than one year between their last seronegative and
first seropositive visits, and 11 of these had viral load and CD4
measurements within 6 to 18 months of seroconversion. For our
tests of seroconversion year versus rate (slope) of CD4 cell decline,
412 men contributed at least two measurements within three years
following seroconversion and had no missing information on race,
age, and CCR5D32 genotype, and thus contributed to the
multivariate analysis.
Laboratory Methods
At each semiannual MACS visit, absolute CD4+ T lymphocyte
counts were obtained by flow cytometry [32] and an automated
complete blood count and differential determined. HIV-1 RNA
was measured in stored plasma samples by reverse-transcription
polymerase chain reaction (RT-PCR) (AMPLICOR HIV-1
MONITOR Test, Roche Diagnostics, Nutley, NJ) with assay
detection limits of 400 (Standard Assay) and 50 (UltraSensitive
Assay) copies/mL.
Statistical Analysis
We performed univariate and multivariate linear regression of the
association between date of seroconversion (independent) and
prognostic markers of HIV infection (dependent): 1) plasma viral
load (log10 copies/mL) at the second (,9 months) and third
(,15 months) seropositive visits; 2) the CD4 cell count (square
root-transformed to achieve approximate normality) at the second
and third seropositive visits; and 3) slope of the CD4 cell decline
per year within three years after seroconversion. Covariates
included MACS center location (Baltimore, Chicago, Los Angeles,
Pittsburgh), race (Black non-Hispanic, Hispanic, White non-
Hispanic, and other), age at seroconversion (centered at 30 years
old), and CCR5 gene status (homozygous wild type vs.
heterozygous D32). Statistical associations were performed using
SAS 9.1 (SAS institute, Cary NC). Graphs for figures were
generated using S-Plus 6.2 (Insightful Corporation, Seattle, WA).
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